Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antitumor, monoclonal antibodies | 5435 | 1879925-92-4 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Naxitamab-gqgk is a glycolipid disialoganglioside (GD2)-binding recombinant humanized monoclonal IgG1 antibody, that contains human framework regions and murine complementarity-determining regions. Naxitamab-gqgk binds to the glycolipid GD2. GD2 is a disialoganglioside that is overexpressed on neuroblastoma cells and other cells of neuroectodermal origin, including the central nervous system and peripheral nerves. In vitro, naxitamab-gqgk was able to bind to cell surface GD2 and induce complement dependent cytotoxicity (CDC) and antibody dependent cell-mediated cytotoxicity (ADCC).
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Nov. 25, 2020 | FDA | Y-MABS THERAPEUTICS INC |
None
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hypotension | 72.63 | 59.11 | 31 | 224 | 523818 | 110065226 |
None
| Source | Code | Description |
|---|---|---|
| ATC | L01FX21 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES Other monoclonal antibodies and antibody drug conjugates |
| FDA MoA | N0000191499 | Glycolipid Disialoganglioside-directed Antibody Interactions |
| FDA EPC | N0000191500 | Glycolipid Disialoganglioside-directed Antibody |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Neuroblastoma | indication | 432328008 | DOID:769 |
None
None
None
None
None
None
| ID | Source |
|---|---|
| D11416 | KEGG_DRUG |
| 9K8GNJ2874 | UNII |
| C4733494 | UMLSCUI |
| CHEBI:757411 | CHEBI |
| CHEMBL4297984 | ChEMBL_ID |
| DB15965 | DRUGBANK_ID |
| 10918 | INN_ID |
| C000718263 | MESH_SUPPLEMENTAL_RECORD_UI |
| 11341 | IUPHAR_LIGAND_ID |
| 1137637004 | SNOMEDCT_US |
| 1137667005 | SNOMEDCT_US |
| 4039899 | VANDF |
| 4039900 | VANDF |
| 341259 | MMSL |
| 39053 | MMSL |
| d09688 | MMSL |
| 018572 | NDDF |
| 2474039 | RXNORM |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| DANYELZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50633-230 | INJECTION | 40 mg | INTRAVENOUS | BLA | 31 sections |
| DANYELZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73042-201 | INJECTION | 40 mg | INTRAVENOUS | BLA | 31 sections |